据官方消息，由区块链基础设施自动化公司 Zeeve 提供支持的平行链部署工具 Perfuse 已获得 Web3 基金会 Decentralized Futures 资助，具体金额暂未披露，该 ...

编辑推荐： 为解决股骨头坏死（ONFH）患者早期治疗、预防病情进展及转换为全髋关节置换术（THA）的问题，研究人员开展了用减压系统联合生物疗法（PERFUSE）治疗早期 ONFH 患者的研究。结果显示可改善髋关节评分、延迟塌陷，为早期 ONFH 治疗提供了新途径。

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma Provided by PR Newswire May 6, 2025, 2:00:00 PM ...

Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma.

SAN FRANCISCO, July 20, 2023 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases is pleased to ...

– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the ...

Perfuse Therapeutics Announces Oral Presentation on PER-001 Intravitreal Implant for Glaucoma at the Association for Research in Vision and Ophthalmology (ARVO) Meeting Perfuse Therapeutics ...

Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced positive 24-week ...

Perfuse Therapeutics Inc. has received FDA approval of its IND application for a first-in-human phase I/IIa study of PER-001 intravitreal implant in patients with glaucoma. The trial will enroll ...

This milestone marks transition of Perfuse Therapeutics to a clinical-stage company SAN FRANCISCO, April 4, 2023 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering ...

Perfuse Therapeutics' drug-device PER-001 shows promise in treating glaucoma and diabetic retinopathy, potentially restoring vision in patients.